Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

Oxford PharmaGenesis welcomes Christopher Rains on board as our first Non-Executive Director

Oxford PharmaGenesis is proud to announce the appointment of Christopher Rains as our first Non-Executive Director, strengthening the Board with over 30 years of experience in the pharmaceutical industry. A...

Oxford PharmaGenesis

- PMLiVE

FDA approves Arcutis’ Zoryve cream to treat mild-to-moderate atopic dermatitis

Approximately 16.5 million adults and 9.6 million children in the US are affected by the inflammatory skin condition

- PMLiVE

Bristol Myers Squibb’s Opdualag approved by SMC for advanced melanoma

The fifth-most common cancer in the UK affects more than 1,200 people in Scotland every year

- PMLiVE

Sanofi/Regeneron’s Dupixent shows significant improvements in paediatric eosinophilic oesophagitis

The chronic inflammatory disease affects approximately one in 2,000 people in the US

- PMLiVE

Study reveals GLP-1s could reduce risk of cancer in patients with type 2 diabetes

GLP-1 treatment reduced the risk of gallbladder cancer by 65% and meningioma by 63%

- PMLiVE

Seijaku announces winner of GROW STRESSWISE competition

The Communiqué 2024 competition winner has been announced as Pippa Perrett from Lumanity

- PMLiVE

Online Investigator Meetings: A Customer Story

Discover how Impetus Digital transformed a multicenter Phase III clinical trial with their innovative virtual solutions.

Impetus Digital

- PMLiVE

Medscape Education Showcases Unprecedented Achievements at EHA 2024

Medscape Education is proud to share its monumental success at the EHA 2024 Congress. Our continued commitment to patient-centric medical education was evident throughout the event, with notable achievements and...

Medscape Education

- PMLiVE

Eli Lilly to expand chronic disease pipeline with $3.2bn Morphic acquisition

The deal includes a candidate in mid-stage clinical development for inflammatory bowel disease

- PMLiVE

Communiqué Awards

Announcement about the results of the Media Relations category

- PMLiVE

AstraZeneca’s Imfinzi regimen approved by MHRA to treat resectable lung cancer

The drug is now approved in Great Britain to treat both resectable and unresectable NSCLC

- PMLiVE

J&J and Legend share positive late-stage results for Carvykti in multiple myeloma

More than 35,000 new cases of the blood cancer are expected to be diagnosed in the US this year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links